CHANGE REQUEST 1241

<table>
<thead>
<tr>
<th>HEADER SECTION NUMBERS</th>
<th>PAGES TO INSERT</th>
<th>PAGES TO DELETE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of Contents</td>
<td>2 pp.</td>
<td>2 pp.</td>
</tr>
<tr>
<td>30-1</td>
<td>4 pp.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NEW/REVISED MATERIAL--EFFECTIVE DATE: September 19, 2000
IMPLEMENTATION DATE: September 19, 2000

Section 30-1, Routine Costs of Clinical Trials, creates a new section to implement new policy to cover routine costs in clinical trials. This policy is in accordance with the June 7, 2000, executive memorandum from the President of the United States to provide coverage of routine patient care costs in clinical trials.

This national coverage policy is based upon the authority found in §1862(a)(1)(E) of the Social Security Act (the Act). It is binding on all Medicare carriers, intermediaries, peer review organizations, health maintenance organizations, competitive medical plans, health care prepayment plans, and Medicare+Choice organizations (§1852(a)(1)(A) of the Act). In addition, an administrative law judge may not disregard, set aside, or otherwise review a national coverage decision issued under §1862(a)(1) of the Act. 42 C.F.R. §405.860

DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previous published in the manual and is only being reprinted.

Funding is available through the Supplemental Budget Request process for costs required to implement these instructions.
COVERAGE ISSUES

Clinical Trials

| Routine Costs in Clinical Trials | 30-1 |

Medical Procedures

Colonic Irrigation 35-1
Manipulation 35-2
Heat Treatment, Including the Use of Diathermy and Ultrasound for Pulmonary Conditions 35-3
Ultrasonic Surgery 35-4
Cellular Therapy 35-5
Thermogenic Therapy 35-6
Carotid Body Resection/Carotid Body Denervation 35-7
Acupuncture 35-8
Phaco-Emulsification Procedure-Cataract Extraction 35-9
Hyperbaric Oxygen Therapy 35-10
Sterilization 35-11
Plastic Surgery to Correct "Moon Face" 35-12
Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections With Sclerosing Agents 35-13
Consultations With a Beneficiary's Family and Associates 35-14
Postural Drainage Procedures and Pulmonary Exercises 35-15
Vitrectomy 35-16
Induced Lesions of Nerve Tracts 35-17
Electrosleep Therapy 35-18
Intravenous Histamine Therapy 35-19
Treatment of Motor Function Disorders With Electric Nerve Stimulation 35-20
Inpatient Hospital Pain Rehabilitation Programs 35-21
Outpatient Hospital Pain Rehabilitation Programs 35-21.1
Inpatient Hospital Stays for the Treatment of Alcoholism 35-22
Outpatient Hospital Services for Treatment of Alcoholism 35-22.1
Treatment of Drug Abuse (Chemical Dependency) 35-22.2
Treatment of Alcoholism and Drug Abuse in a Freestanding Clinic 35-22.3
Chemical Aversion Therapy for Treatment of Alcoholism 35-23
Electrical Aversion Therapy for Treatment of Alcoholism (Electroversion Therapy, Electro-Shock Therapy, Noxious Paradic Stimulation) 35-23.1
Diagnosis and Treatment of Impotence 35-24
Cardiac Rehabilitation Programs 35-25
Treatment of Obesity 35-26
Supplemented Fasting 35-26.1
Biofeedback Therapy 35-27
Oxygen Treatment of Inner Ear/Carbon Therapy 35-29
Blood Platelet Transfusions and Bone Marrow Transplantation 35-30
Stem Cell Transplantation 35-30.1
Treatment of Decubitus Ulcers 35-31

Rev. 126
COVERAGE ISSUES

Medical Procedures

Vertebral Artery Surgery 35-32
Intestinal By-Pass Surgery 35-33
Fabric Wrapping of Abdominal Aneurysms 35-34
Therapeutic Embolization 35-35
Extracranial-Intracranial (EC-IC) Arterial Bypass Surgery 35-37
Ultrafiltration, Hemoperfusion and Hemofiltration 35-38
Intraocular Photography 35-39
Gastric Bypass Surgery for Obesity 35-40
Diathermy Treatment 35-41
Withdrawal Treatments for Narcotic Addictions 35-42
Use of Visual Tests Prior to and General Anesthesia During Cataract Surgery 35-44
Cardiac Catheterization Performed in Other Than a Hospital Setting 35-45
Assessing Patient's Suitability for Electrical Nerve Stimulation Therapy 35-46
Breast Reconstruction Following Mastectomy 35-47
Osteogenic Stimulation 35-48
Hyperthermia for Treatment of Cancer 35-49
Cochleostomy with Neurovascular Transplant for Meniere's Disease 35-50
Hemodialysis for Treatment of Schizophrenia 35-51
Laser Procedures 35-52
Adult Liver Transplantation 35-53
Pediatric Liver Transplantation 35-53.1
Refractive Keratoplasty 35-54
Transvenous (Catheter) Pulmonary Embolectomy 35-55
Fluidized Therapy Dry Heat for Certain Musculoskeletal Disorders 35-56
Electroencephalographic Monitoring During Surgical Procedures Involving the Cerebral Vasculature 35-57
Electroencephalographic (EEG) Monitoring During Open-Heart Surgery 35-57.1
Thoracic Duct Drainage (TDD) in Renal Transplants 35-58
Endoscopy 35-59
Apheresis (Therapeutic Pheresis) 35-60
Transsexual Surgery 35-61
Invasive Intracranial Pressure Monitoring 35-62
Tinnitus Masking 35-63
Chelation Therapy for Treatment of Atherosclerosis 35-64
Gastric Freezing 35-65
Treatment of Psoriasis 35-66
Melodic Intonation Therapy 35-67
Implantation of Anti-Gastroesophageal Reflux Device 35-69
Closed-Loop Blood Glucose Control Device (CBGCD) 35-70
30-1 ROUTINE COSTS IN CLINICAL TRIALS

Effective for items and services furnished on or after September 19, 2000, Medicare covers the routine costs of qualifying clinical trials, as such costs are defined below, as well as reasonable and necessary items and services used to diagnose and treat complications arising from participation in all clinical trials. All other Medicare rules apply.

Routine costs of a clinical trial include all items and services that are otherwise generally available to Medicare beneficiaries (i.e., there exists a benefit category, it is not statutorily excluded, and there is not a national noncoverage decision) that are provided in either the experimental or the control arms of a clinical trial except:

- The investigational item or service, itself;
- Items and services provided solely to satisfy data collection and analysis needs and that are not used in the direct clinical management of the patient (e.g., monthly CT scans for a condition usually requiring only a single scan); and
- Items and services customarily provided by the research sponsors free of charge for any enrollee in the trial.

Routine costs in clinical trials include:

- Items or services that are typically provided absent a clinical trial (e.g., conventional care);
- Items or services required solely for the provision of the investigational item or service (e.g., administration of a noncovered chemotherapeutic agent), the clinically appropriate monitoring of the effects of the item or service, or the prevention of complications; and
- Items or services needed for reasonable and necessary care arising from the provision of an investigational item or service—in particular, for the diagnosis or treatment of complications.

This policy does not withdraw Medicare coverage for items and services that may be covered according to local medical review policies or the regulations on category B investigational device exemptions (IDE) found in 42 C.F.R. §405.201-405.215 and §411.15 and §411.406. For information about LMRPs, refer to www.lmrp.net, a searchable database of Medicare contractors’ local policies.
For noncovered items and services, including items and services for which Medicare payment is statutorily prohibited, Medicare only covers the treatment of complications arising from the delivery of the noncovered item or service and unrelated reasonable and necessary care. (Refer to MCM §§2300.1 and MIM 3101.) However, if the item or service is not covered by virtue of a national noncoverage policy in the Coverage Issues Manual and is the focus of a qualifying clinical trial, the routine costs of the clinical trial (as defined above) will be covered by Medicare but the noncovered item or service, itself, will not.

A. Requirements for Medicare Coverage of Routine Costs.--Any clinical trial receiving Medicare coverage of routine costs must meet the following three requirements:

1. The subject or purpose of the trial must be the evaluation of an item or service that falls within a Medicare benefit category (e.g., physicians' service, durable medical equipment, diagnostic test) and is not statutorily excluded from coverage (e.g., cosmetic surgery, hearing aids).

2. The trial must not be designed exclusively to test toxicity or disease pathophysiology. It must have therapeutic intent.

3. Trials of therapeutic interventions must enroll patients with diagnosed disease rather than healthy volunteers. Trials of diagnostic interventions may enroll healthy patients in order to have a proper control group.

The three requirements above are insufficient by themselves to qualify a clinical trial for Medicare coverage of routine costs. Clinical trials also should have the following desirable characteristics; however, some trials, as described below, are presumed to meet these characteristics and are automatically qualified to receive Medicare coverage:

1. The principal purpose of the trial is to test whether the intervention potentially improves the participants' health outcomes;

2. The trial is well-supported by available scientific and medical information or it is intended to clarify or establish the health outcomes of interventions already in common clinical use;

3. The trial does not unjustifiably duplicate existing studies;

4. The trial design is appropriate to answer the research question being asked in the trial;

5. The trial is sponsored by a credible organization or individual capable of executing the proposed trial successfully;

6. The trial is in compliance with Federal regulations relating to the protection of human subjects; and

7. All aspects of the trial are conducted according to the appropriate standards of scientific integrity.
B. Qualification Process for Clinical Trials.--Using the authority found in §1142 of the Act (cross-referenced in §1862(a)(1)(E) of the Act), the Agency for Healthcare Research and Quality (AHRQ) will convene a multi-agency Federal panel (the "panel") composed of representatives of the Department of Health and Human Services research agencies (National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), AHRQ, and the Office of Human Research Protection), and the research arms of the Department of Defense (DOD) and the Department of Veterans Affairs (VA) to develop qualifying criteria that will indicate a strong probability that a trial exhibits the desirable characteristics listed above. These criteria will be easily verifiable, and where possible, dichotomous. Trials that meet these qualifying criteria will receive Medicare coverage of their associated routine costs. This panel is not reviewing or approving individual trials. The multi-agency panel will meet periodically to review and evaluate the program and recommend any necessary refinements to HCFA.

Clinical trials that meet the qualifying criteria will receive Medicare coverage of routine costs after the trial's lead principal investigator certifies that the trial meets the criteria. This process will require the principal investigator to enroll the trial in a Medicare clinical trials registry, currently under development.

Some clinical trials are automatically qualified to receive Medicare coverage of their routine costs because they have been deemed by AHRQ, in consultation with the other agencies represented on the multi-agency panel to be highly likely to have the above-listed seven desirable characteristics of clinical trials. The principal investigators of these automatically qualified trials do not need to certify that the trials meet the qualifying criteria, but must enroll the trials in the Medicare clinical trials registry for administrative purposes, once the registry is established.

Effective September 19, 2000, clinical trials that are deemed to be automatically qualified are:

1. Trials funded by NIH, CDC, AHRQ, HCFA, DOD, and VA;
2. Trials supported by centers or cooperative groups that are funded by the NIH, CDC, AHRQ, HCFA, DOD and VA;
3. Trials conducted under an investigational new drug application (IND) reviewed by the FDA; and
4. Drug trials that are exempt from having an IND under 21 CFR 312.2(b)(1) will be deemed automatically qualified until the qualifying criteria are developed and the certification process is in place. At that time the principal investigators of these trials must certify that the trials meet the qualifying criteria in order to maintain Medicare coverage of routine costs. This certification process will only affect the future status of the trial and will not be used to retroactively change the earlier deemed status.

Medicare will cover the routine costs of qualifying trials that either have been deemed to be automatically qualified or have certified that they meet the qualifying criteria unless HCFA's Chief Clinical Officer subsequently finds that a clinical trial does not meet the qualifying criteria or jeopardizes the safety or welfare of Medicare beneficiaries.
Should HCFA find that a trial's principal investigator misrepresented that the trial met the necessary qualifying criteria in order to gain Medicare coverage of routine costs, Medicare coverage of the routine costs would be denied under §1862(a)(1)(E) of the Act. In the case of such a denial, the Medicare beneficiaries enrolled in the trial would not be held liable (i.e., would be held harmless from collection) for the costs consistent with the provisions of §1879, §1842(l), or §1834(j)(4) of the Act, as applicable. Where appropriate, the billing providers would be held liable for the costs and fraud investigations of the billing providers and the trial's principal investigator may be pursued.

Medicare regulations require Medicare+Choice (M+C) organizations to follow HCFA's national coverage decisions. This NCD raises special issues that require some modification of most M+C organizations' rules governing provision of items and services in and out of network. The items and services covered under this NCD are inextricably linked to the clinical trials with which they are associated and cannot be covered outside of the context of those clinical trials. M+C organizations therefore must cover these services regardless of whether they are available through in-network providers. M+C organizations may have reporting requirements when enrollees participate in clinical trials, in order to track and coordinate their members' care, but cannot require prior authorization or approval.